In June 2007，Sichuan Clover was established as a research laboratory.
In July 2016，Sichuan Clover entered into an agreement to establish and build 32,000 sqm commercial-scale cGMP biomanufacturing facility in Changxing, Zhejiang Province, China.
In December 2017，We completed the Series A Investment and raised approximately RMB62.8 million.
In June 2018，Our first patient was dosed with SCB-313 for treatment of cancer patients with malignant ascites in Phase 1 clinical trial.
In November 2019，We completed the Series B Investment and raised approximately RMB304.1 million.
In January 2020，We initiated development of SCB-2019 (CpG 1018/Alum), our COVID-19 vaccine candidate.
In April 2020，We obtained funding from and established collaboration with CEPI for SCB-2019 (CpG 1018/Alum).
In June 2020，We completed the Series B-2 Investment and raised approximately RMB171.8 million.
In June 2020，Our first participant was dosed with SCB-2019 (CpG 1018/Alum) in Phase I clinical trial.
In November 2020，CEPI extended partnership with us to fund up to US$328 million for SCB-2019 (CpG 1018/Alum) through global Phase 2 and Phase 3 clinical trial.
In December 2020，We announced positive Phase 1 data for SCB-2019 (CpG 1018/Alum), our COVID-19 vaccine candidates.
In February 2021，We completed the Series C Investment and raised approximately US$230 million.
In March 2021，We initiated SPECTRA, a pivotal global Phase 2/3 clinical trial evaluating SCB 2019 (CpG 1018/Alum) for vaccine efficacy and dosed the first participant at a clinical trial site located in the Philippines.